Melanocytes arise from neural crest cells and are frequently found in the skin. However, melanocytes are also found in mucosal membranes. Melanocytes in mucosal membranes are distributed to the oral cavity, nasal cavity, paranasal sinuses, esophagus, larynx, vagina, cervix, rectum, and anus. Melanoma results from a malignant change of melanocytes. Melanoma in the head and neck account for upward of 25% of all melanomas. Mucosal melanomas account for less than 1% of all melanoma. However, mucosal melanoma accounts for roughly 10% of melanoma of the head and neck. The most common sites for mucosal melanoma in order are nasal, paranasal sinuses, oral cavity, and nasopharynx. Of all mucosal melanomas, paranasal sinus has the worst prognosis. The best prognosis locations are the nasal and oral cavity. In 1885, the first case of oral melanoma was reported. Approximately 80% of oral malignant melanomas develop in the mucosa of the upper jaws (maxillary anterior gingiva). Majority of these lesions occur in the keratinizing mucosa of the palate and alveolar gingivae. Lesions are frequently asymptomatic until ulceration and hemorrhage are present. Compared with other melanomas, mucosal melanomas have the lowest percentage of 5-year survival. There is a poor 5-year survival at approximately 15% to 30% likely due to delayed detection.
Etiology is mostly unclear in malignant melanoma of the mouth. Mucosal melanoma of the mouth is not related to sun exposure. Risk factors largely remain obscure. Denture irritation, alcohol, and cigarette smoking have been listed as possible risk factors, but a direct relation is not substantiated.
The peak age for diagnosis of mucosal melanoma is between 65 and 79 years, which is 1 to 2 decades later than cutaneous melanoma. Mucosal melanomas are found more so in women than in men. However, in oral malignant melanoma, gender distribution is reported as 1:1. Melanoma of the lip has a slightly male predominance. Malignant melanoma of the mouth has a higher prevalence in blacks, Japanese, and Indians of Asia. The higher prevalence may be due to the higher published reports than actual rates.
Melanoma develops from a malignant transformation of melanocytes. A number of pathways have been identified.
Mutations in c-KIT
Recent data indicates that c-KIT (CD117) is overexpressed in upward of 80% of mucosal melanoma cases. This pathway is important and common in acral and mucosal melanoma, melanomas unrelated to sun exposure. KIT is a transmembrane tyrosine kinase receptor that is expressed on hematopoietic progenitor cells, melanocytes, mast cells, primordial germ cells, and interstitial cells of Cajal. Activating mutations and amplifications cause activation of growth and proliferation pathways. New drugs, such as imatinib, work on this pathway.
Mutations in BRAF
Bioinformatics Resources and Applications Facility (BRAF) protein mutations are uncommon in mucosal melanoma and found at less than 10% of cases. However, in cutaneous melanoma, BRAF mutations are found in up to 80% of melanomas.
The mucosa of the mouth differs from the skin. Due to the lack of histological landmarks that are analogous to the papillary, reticular dermis, and muscle bundles, a pathological leveling system and description cannot be applied properly for mucosal melanomas. Therefore, use of Clark’s levels, which are commonly used in cutaneous melanoma, are unable to be used. Many melanomas in the mouth have a histologic with lentigo maligna melanoma in a radial growth phase.
The mucosal melanomas can show 2 principal patterns: an in situ pattern and an invasive pattern. Approximately 15% of cases of oral melanoma are in situ mucosal lesions, 30% of cases are invasive lesions, and 55% of cases have a combined pattern of invasive with in situ components. Most advanced lesions have a combination pattern of invasive melanoma with in situ component.
The initial presentation of malignant melanoma of the mouth is often swelling that is usually with a brown, dark blue, or black macule. Satellite foci may surround the primary lesion. Just like cutaneous melanomas, melanoma in the mouth may be asymmetric with irregular borders. In amelanotic melanomas, pigmentation is not present. Amelanotic melanomas may simulate pyogenic granulomas. Many times, due to late diagnosis, erythema and ulceration may be present.
Surgery is the mainstay of treatment in oral malignant melanoma. Radical excision with disease-free margins is the first goal in the surgical management. Diagnostic excisional biopsy followed by wide local excision where the diagnosis is proven. Following complete surgical excision, relapse rates have been reported to be 10% to 20%.
In a clinically positive neck, a neck dissection is mandatory in all cases of head and neck mucosal melanoma that is amenable to radical treatment.
Sentinel Lymph Node Biopsy/Lymphoscintigraphy
Has less value in staging and is less useful in predicting lymphatic drainage patterns in oral melanoma.
Radiotherapy is used to control local disease. This is in contrast to cutaneous melanoma. Radiotherapy is valuable in the goal of achieving relapse-free survival.
Due to the low incidence of oral melanoma, well-controlled trials with large participants have been limited. Chemotherapy and immunotherapy may have a role in the prevention of metastatic disease.
The differential diagnosis of oral melanoma involves anything that can cause pigmentation within the mouth:
There is no T1 or T2 in mucosal melanoma.
Lymph Nodes, N
Distant Metastases, M
Overall, the prognosis of malignant melanoma is poor with a 5-year survival at most 30% often due to late diagnosis.
Independent prognostic factors that have been suggested are:
After complete surgical excision, relapse rates have been reported to be 10% to 20%. Recurrence has been noted even up to 11 years following surgery.
Metastases to the lymph nodes of the neck, lungs, liver, and brain
Melanoma care and treatment requires a multidisciplinary approach. Melanomas of the head and neck, specifically the mouth, have a poor prognosis and often have advanced disease. Consultations with otolaryngology (head and neck surgery), surgical oncology, pathology, speech therapy, and other specialists depending on complications and distant metastases are warranted.
Patients with a history of oral melanoma require lifelong follow-up.
Primary mucosal melanomas are aggressive tumors that are rarer than cutaneous melanoma. Head and neck mucosal melanomas are the most common. Wide excision is the treatment of choice. Oral melanoma complicated in that detection does not usually occur until the lesion is advanced. Overall 5-year survival is low which highlights the need for aggressive treatment and continued follow-up afterward. Detection of c-KIT mutations has been identified in upwards of 80% of mucosal melanomas and as little as 10% of BRAF mutations; this is opposite of cutaneous melanoma. Newer drugs such as imatinib are used in c-KIT pathway melanomas. It is important to maintain a high index of suspicion with pigmented lesions within the oral cavity, especially those in sites most common to oral melanoma (palate and maxillary gingiva).
The management of oral malignant melanoma is with a multidisciplinary team that includes an oncologist, oral surgeon, head and neck surgeon, plastic surgeon, radiation therapist, and a pulmonologist. Surgery is the mainstay of treatment in oral malignant melanoma. Radical excision with disease-free margins is the first goal in the surgical management. In general, primary mucosal melanomas are aggressive tumors that are rarer than cutaneous melanoma. Oral melanoma complicated in that detection does not usually occur until the lesion is advanced. Overall 5-year survival is low which highlights the need for aggressive treatment and continued follow-up afterward. Newer drugs such as imatinib are used in c-KIT pathway melanomas. The primary care physician and nurse provider should always maintain a high index of suspicion with pigmented lesions within the oral cavity, especially those in sites most common to oral melanoma (palate and maxillary gingiva). Due to the low incidence of oral melanoma, well-controlled trials with large participants have been limited. (Level V)
|||Unusual Cancers of Childhood Treatment (PDQ®): Health Professional Version 2002; [PubMed PMID: 26389315]|
|||Panda S,Dash S,Besra K,Samantaray S,Pathy PC,Rout N, Clinicopathological study of malignant melanoma in a regional cancer center. Indian journal of cancer. 2018 Jul-Sep; [PubMed PMID: 30693897]|
|||Natarajan E, Black and Brown Oro-facial Mucocutaneous Neoplasms. Head and neck pathology. 2019 Jan 29; [PubMed PMID: 30693458]|
|||Lee JS,Lee H,Lee S,Kang JH,Lee SH,Kim SG,Cho ES,Kim NH,Yook JI,Kim SY, Loss of SLC25A11 causes suppression of NSCLC and melanoma tumor formation. EBioMedicine. 2019 Jan 24; [PubMed PMID: 30686754]|
|||Markman RL,Rosa GA,Cardili L,Simonato LE,Brandão TB,Ribeiro AC, Tongue metastasis of cutaneous melanoma: Report of two cases and literature review. Journal of clinical and experimental dentistry. 2018 Nov; [PubMed PMID: 30607233]|
|||Mayo Z,Seyedin S,Marquardt M,Mohiuddin I,Milhem M,Liu V,Pagedar N,Anderson C, Cutaneous malignant melanoma of the oral cavity following skin graft reconstruction: Case report. Head [PubMed PMID: 30537068]|
|||Maymone MBC,Greer RO,Kesecker J,Sahitya PC,Burdine LK,Cheng AD,Maymone AC,Vashi NA, Premalignant and Malignant Mucosal lesions: Clinical and Pathological Findings Part II. Premalignant and malignant mucosal lesions. Journal of the American Academy of Dermatology. 2018 Nov 14; [PubMed PMID: 30447325]|
|||Williams MD,Franchi A,Helliwell T,Müller S,Thompson LDR, Data Set for Reporting of Mucosal Melanomas of the Head and Neck: Explanations and Recommendations of the Guidelines From the International Collaboration on Cancer Reporting. Archives of pathology [PubMed PMID: 30500297]|
|||Oranges CM,Sisti G,Nasioudis D,Tremp M,DI Summa PG,Kalbermatten DF,Largo RD,Schaefer DJ, Hard Palate Melanoma: A Population-based Analysis of Epidemiology and Survival Outcomes. Anticancer research. 2018 Oct; [PubMed PMID: 30275204]|
|||Dalal AJ,Ingham J,Collard B,Merrick G, Review of outcomes of 500 consecutive cases of non-melanoma skin cancer of the head and neck managed in an oral and maxillofacial surgical unit in a District General Hospital. The British journal of oral [PubMed PMID: 30219606]|